ANTIVIRAL PROPERTIES OF RO 31-8959, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PROTEINASE

被引:156
作者
CRAIG, JC
DUNCAN, IB
HOCKLEY, D
GRIEF, C
ROBERTS, NA
MILLS, JS
机构
[1] NATL INST BIOL STAND & CONTROLS,DEPT ELECTRON MICROSCOPY,S MIMMS,HERTS,ENGLAND
[2] NATL INST BIOL STAND & CONTROLS,CTR AIDS COLLABORAT,S MIMMS,HERTS,ENGLAND
关键词
HIV; PROTEINASE; INHIBITOR;
D O I
10.1016/0166-3542(91)90045-S
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ro 31-8959 inhibits the spread of HIV infection and the production of cytopathic effects in cultures of acutely infected cells. IC50 values for these effects are in the range 0.5 - 6.0 nM and IC90 values are in the range 6.0 - 30.0 nM. This inhibitor is effective even when added to cultures at a late stage of infection, after syncytia have started to form. Virus antigen, virus particles and virus cytopathic effects can largely be cleared from cultures treated with compound from 3 days until 6 days post infection. In chronically-infected cells, inhibition of virus maturation can be detected after 24 hours' treatment with 10 nM Ro 31-8959. In addition, a significant reduction of the proteolytic processing of p56 to p24 can be demonstrated in these cells with compound at picomolar concentrations. These properties indicate that Ro 31-8959 is highly effective against HIV with the potential to inhibit acute, established acute and chronic infections.
引用
收藏
页码:295 / 305
页数:11
相关论文
共 11 条
[1]   MiniReview: Antiviral Targets Series, Number 1 Targets for antiviral chemotherapy: HIV-proteinase [J].
Dunn, B. M. ;
Kay, J. .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1990, 1 (01) :3-8
[2]   A SIMPLE METHOD OF REDUCING THE FADING OF IMMUNOFLUORESCENCE DURING MICROSCOPY [J].
JOHNSON, GD ;
ARAUJO, GMDN .
JOURNAL OF IMMUNOLOGICAL METHODS, 1981, 43 (03) :349-350
[3]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[4]   HTLV-III GAG PROTEIN IS PROCESSED IN YEAST-CELLS BY THE VIRUS POL-PROTEASE [J].
KRAMER, RA ;
SCHABER, MD ;
SKALKA, AM ;
GANGULY, K ;
WONGSTAAL, F ;
REDDY, EP .
SCIENCE, 1986, 231 (4745) :1580-1584
[5]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[6]   A SYNTHETIC HIV-1 PROTEASE INHIBITOR WITH ANTIVIRAL ACTIVITY ARRESTS HIV-LIKE PARTICLE MATURATION [J].
MCQUADE, TJ ;
TOMASSELLI, AG ;
LIU, L ;
KARACOSTAS, V ;
MOSS, B ;
SAWYER, TK ;
HEINRIKSON, RL ;
TARPLEY, WG .
SCIENCE, 1990, 247 (4941) :454-456
[7]   INHIBITION OF HIV-1 PROTEASE IN INFECTED LYMPHOCYTES-T BY SYNTHETIC PEPTIDE ANALOGS [J].
MEEK, TD ;
LAMBERT, DM ;
DREYER, GB ;
CARR, TJ ;
TOMASZEK, TA ;
MOORE, ML ;
STRICKLER, JE ;
DEBOUCK, C ;
HYLAND, LJ ;
MATTHEWS, TJ ;
METCALF, BW ;
PETTEWAY, SR .
NATURE, 1990, 343 (6253) :90-92
[8]   ROLE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1-SPECIFIC PROTEASE IN CORE PROTEIN MATURATION AND VIRAL INFECTIVITY [J].
PENG, C ;
HO, BK ;
CHANG, TW ;
CHANG, NT .
JOURNAL OF VIROLOGY, 1989, 63 (06) :2550-2556
[9]   COMPLETE NUCLEOTIDE-SEQUENCE OF THE AIDS VIRUS, HTLV-III [J].
RATNER, L ;
HASELTINE, W ;
PATARCA, R ;
LIVAK, KJ ;
STARCICH, B ;
JOSEPHS, SF ;
DORAN, ER ;
RAFALSKI, JA ;
WHITEHORN, EA ;
BAUMEISTER, K ;
IVANOFF, L ;
PETTEWAY, SR ;
PEARSON, ML ;
LAUTENBERGER, JA ;
PAPAS, TS ;
GHRAYEB, J ;
CHANG, NT ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1985, 313 (6000) :277-284
[10]   RATIONAL DESIGN OF PEPTIDE-BASED HIV PROTEINASE-INHIBITORS [J].
ROBERTS, NA ;
MARTIN, JA ;
KINCHINGTON, D ;
BROADHURST, AV ;
CRAIG, JC ;
DUNCAN, IB ;
GALPIN, SA ;
HANDA, BK ;
KAY, J ;
KROHN, A ;
LAMBERT, RW ;
MERRETT, JH ;
MILLS, JS ;
PARKES, KEB ;
REDSHAW, S ;
RITCHIE, AJ ;
TAYLOR, DL ;
THOMAS, GJ ;
MACHIN, PJ .
SCIENCE, 1990, 248 (4953) :358-361